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Amantadine, or 1-adamantanamine hydrochloride, has been reported to possess 
activity against influenza virus in vitro, in mice and in man,*-4 and against rubella 
virus in v i m 5  The scope and mechanism of its activity, therefore, are of particular 
interest. This report describes the activity of amantadine against other respiratory 
viruses and offers new information concerning its site of action. 
Materials and Methods 
Tissue culture techniques. HeLa cells were infected with strains of parainfluenza 
viruses, types 2 (Greer) or 3 (C 243), obtained from R. M. Chanock, National 
Institutes of Health, Bethesda, Md. The LLC-MK2 line of monkey kidney cells6 
was used for parainfluenza 3 and the WM strain of rubella v i r u ~ e s . ~  Other studies 
with rubella virus involved the chronically infected line previously described.8 
The Long strain of respiratory syncytial virus, obtained from the American Type 
Culture Collection and grown in the H-L line of human epithelial cells, and the 
Japan 305 strain of influenza virus grown in primary calf kidney cells, were also 
used. Virus was detected by hemagglutination of guinea pig erythrocytes, by 
titration of infectivity, or by cytopathogcnic effect, depending on the particular 
cell-virus system. Antiviral activity was evaluated either by comparison of virus 
yield from treated and control cultures when measured by relative cytopathology, 
hemagglutination, or infectivity titrations, or by calculation of a therapeutic 
index? 
In vivo techniques. Swiss Webster mice or yearling ferrets were infected with 
influenza virus by a 30-minute exposure to aerosols of diluted suspensions of in- 
fected mouse lungs. The WR strain of vaccinia virus was given to mice intra- 
nasally. Disease was evaluated either by lung lesion scores10 or by mean survival 
times.' X-ray was given as previously described.11 
Results 
Inhibition of myxoviruses in vitro. The problems of diagnosis and estimation 
of effectiveness make it important to assess the susceptibilities of all pneumotropic 
infectious agents to a drug proposed for any respiratory disease. In addition, the 
sharing of susceptibility to amantadine by several influenza viruses' and rubella 
virus,5 together with the noted similarities12 of rubella virus to the myxovirus 
group, prompted exploration of inhibition by amantadine as a property common 
to myxoviruses. Accordingly, the antiviral activity of amantadine for several 
additional myxoviruses was studied, with the results presented in TABLE 1. The 
HeLa, LLC-MK2 and HL cell lines maintained in our laboratory all tolerated 
62.5 pg. of amantadine hydrochloride per ml., a concentration not directly 
virucidal to any of the viruses used in these experiments. Amantadine hydro- 
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chloride in concentrations up to 62.5 pg.lml. did not inhibit hemagglutinin pro- 
duction in HeLa cells inoculated with parainfluema-2 virus at a multiplicity of 
10: 1. However, when virus yield was measured by infectivity or cytopathology, 
there was inhibition, especially at the higher concentration. With parainfluenza 3 
virus at a multiplicity of 100: 1, measurements of hemagglutinin or cytopathic 
activity did not disclose the inhibition seen in the production of infectious virus. 
At a lower multiplicity of parainfluenza 3 virus of 10: 1, all three measurements- 
hemagglutination, infectivity, and cytopathology-revealed inhibition. With para- 
influenza 3 virus in LLC-MK2 cells at a multiplicity of 10: 1, inhibition of virus 
production was observable whether measured by infectivity or hemagglutination. 
The ability of amantadine hydrochloride to inhibit respiratory syncytial virus was 
detectable by measurement of either the yield of infectivity or by cytopathology. 
These studies show that amantadine hydrochloride can inhibit selected myxo- 
viruses other than influenza when used at high enough concentrations in a suitable 
host-virus system and with sensitive methods of following virus. 
Acrivity in mice and ferrets. Other experiments were directed toward exploring 
the activity of amantadine in v i v a  Data showing the protective effect of amanta- 
dine hydrochloride against aerosol-induced influenza are presented in TABLE 2. It 
is noteworthy that the Lee strain of type B influenza was also susceptible. Vaccinia 
virus, included because of a recent report of its susceptibility in plaque inhibition 
tests,13 was given by intranasal injection. Vaccinia1 lung lesions were not found to 
be inhibited. 
The effectiveness of amantadine in vivo had been demonstrated only in mice' 
before its trial in man.2 Since more than one laboratory animal is usually desir- 
able, amantadine was also tested for activity against influenza using ferrets. 
Amantadine hydrochloride is relatively more toxic for ferrets than for mice. 
Whereas 233 mg./kg. given intravenously is an LD50 for mice,l all ferrets receiv- 
Average lung 
lesion score* 
Virus Treated? Control 
Iduenza, PR 8 1.6 2.6 
Iduenza, A,/AA/2/60 .5 1.2 
Iduenza, B/Lee 2.1 3.4 
Vaccinia, WR 2.4 2.5 
ing a single intraperitoneal dose of 200 mg./kg. of amantadine hydrochloride 
suffered convulsions and died in approximately 30 minutes. Daily intraperitoneal 
doses of 100 mg./kg. were tolerated for only two days, but given orally in two 
daily doses, the same amount was tolerated by ferrets for at least 13 days. Results 
of treating ferrets infected by aerosols of PR8 influenza virus are given in TABLE 
3. From these results it may be seen that in ferrets amantadine hydrochloride 
aggravated rather than alleviated infection with influenza virus. 
Mechanism of action of amantadine: Influence of host immunity. Davies et a1.l 
showed the combination of amantadine with specific antiserum to be more effec- 
tive against influenza in vitro than either treatment separately. This finding and 
other i m p r e s ~ i o n s ~ ~  uggested that antibody might also participate in the antiviral 
activity of amantadine during the early stages of the in vivo infection. To test this 
hypothesis amantadine was studied in mice whose capacity for antibody produc- 
tion was impaired by a large sublethal dose of X-ray. Results of two experiments, 
given in TABLE 4, show that a single whole-body exposure to 350 R one day 
before virus, or treatment with amantadine hydrochloride starting two days be- 
fore virus, provided protection as indicated by the increases in mean survival 
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TABLE 4 
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Number of mice alive each day to day 17.' 
Total number of mice in group 
t 350 R, given in a single dose, one day before virus. 
t 100 or 50 mg./kg./day, subcutaneously X 20, starting two days before virus. 
that their individual effects were additive. Other data from appropriate control 
groups, not given in the Table, showed that amantadine had no significant in- 
fluence on the radiosensitivity of mice. 
Locus of antiviral activity. On the basis of its time of effectiveness and com- 
parison with specific antiserum, it was concluded' that the site of action of 
amantadine was the penetration by the virus of the host cell. The possibility that 
amantadine might be antagonizing an amino acid led to attempts to reverse its 
effect with several amino acids. Proline, tyrosine, phenylalanine, or tryptophane 
failed to alter the abil'ity of amantadine to inhibit influenza virus cytopathology 
in primary calf kidney cell cultures. 
Additional information was sought through comparison of the inhibitory 
activities of amantadine hydrochloride and aminophenylmethane sulfonic acid, 
the latter a type of inhibitor of influenza virus15 whose locus of action has been 
established to be early in the infectious cycle at adsorption or penetration.l6 The 
results, presented in TABLE 5 ,  showed that in primary calf kidney cells infected 
with Japan 305 influenza virus, either amantadine hydrochloride or aminophenyl- 
methane sulfonic acid was ineffective applied postinfection; that either was equally 
TABLE 5 
CROSS TREATMENT OF INFLUENZA VIRUS (A,/JAPAN 305) WITH AMANTADIHE HYDROCHLORIDE 
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effective used preinfection or combined pre- and postinfection. These data further 
show that inhibition due to either compound is maintained by the other. Although 
the inhibitory activity of substituted sulfonic acids has been associated with 
potassium i0n,17 added potassium ion did not reverse either aminophenylamethane 
sulfonic acid or amantadine hydrochloride in the calf kidney system. 
Development of resistance. Since amantadine hydrochloride had been found to 
inhibit acute rubella virus infection in ~ i t r o , ~  i t  was of interest to study its activity 
against the chronically infected cell line (RA) developed in this laboratory.8 The 
results, presented in TABLE 6, show that during four consecutive passages of RA 
cells chronically infected with rubella virus, treatment with amantadine hydro- 
chloride did not reduce the third week virus yield. Subsequently, the persistence 
of rubella virus in amantadine-treated, chronically infected cultures was con- 
firmed by immunofluorescence studies. This lack of inhibition in the chronic in- 
fection might have resulted from the virus becoming resistant during the pro- 
longed growth period. However, when grown in several consecutive-treated acute 
infections, with treated virus used as the inoculum for the following passage, 
rubella virus retained its susceptibility to amantadine, exhibiting the same in- 
hibition as previously untreated virus. Furthermore, when rubella virus from 
treated, chronically infected cells was used as the inoculum for the acute infection 
of LLC-MK2 cells, susceptibility was observed as indicated by a sixth-day virus 
titer of 10-4-7 in untreated control cultures. 
Host cell Amantadine 
# K . / m l .  
Int., 10-0 
Passage 
I 1st 2nd 3rd 4th 
RA (chronic) - 3.5 4.0 4.3 3.1 
31.2 1 3.0 4.3 4.3 3.5 
LLC-MK, (acute) - 4.5 4.3 4.0 4.0 
31.2 1 2.5 2.1 2.1 2.3 
The observed maintenance of the susceptibility of rubella virus to inhibition 
by amantadine in vitro contrasted with the results seen with influenza. When 
influenza virus was grown in primary calf kidney cells in the presence of amanta- 
dine, the development of resistance to inhibition by amantadine was readily 
apparent, as shown in TABLE 7, where antiviral activity is presented as the thera- 
peutic index.g These results show that influenza virus, initially susceptible to 
amantadine (therapeutic index = 16) or aminophenylmethane sulfonic acid 
(therapeutic index = 8) in one passage, albeit with several growth cycles, in the 
presence of either inhibitor lost its susceptibility to both inhibitors. 
Discussion 
The report by Davies et al. on the antiviral activity of amantadine hydro- 
chloride' indicated a limited spectrum of activity among the myxoviruses. Their 
finding that influenza viruses of types A, A,, A*. C, and D (Sendai, para- 
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TABLE I 
SULFONIC A ID BY INFLUENZA VIRUS (&/JAPAN 305) IN PRIMARY 
DEVELOPMENT OF RESISTANCE TO AMANTADINE HCI AND AMINOPHENYLMBTHANE 
CALF KIDNEY CELL CULTURES 
Therapeutic index 
Influenza, Japan 305 passed 1 x 
Influenza, Japan 305, passed 1 x with 
with amantadine HC1 
aminophenylmethane sulfonic acid 
I vs. Amantadine vs. Aminophenylmethane 
HCl sulfonic acid 
1 
1 
Influenza, Japan 305 I l6 8 
1 
1 
influenza), together with the present results, indicate that all types of influenza 
virus can be susceptible. Our results with the parainfluenza and respiratory 
syncytial viruses suggest that the resistance of at least certain myxoviruses may be 
relative rather than absolute, and that susceptibility may not be evident depending 
on the methods and conditions used. The observed inhibition of infectivity with- 
out inhibition of hemagglutination may indicate incomplete virus. Some lines of 
given strains of influenza virus appear to differ in susceptibility, such as the 
lines of influenza B-Lee used by Davies et a/.' and by ourselves, as well as similar 
unpublished experiences of others. However, complicating any consideration of 
the inherent resistance or susceptibility of viruses to amantadine is the ability of 
at least one to develop resistance. It is significant that, although influenza virus 
readily developed resistance in vitro, we have yet to demonstrate the emergence 
of resistance to amantadine in vivo; specifically, in treated mice. In any event, 
amantadine does not engender sufficient resistance to prevent it from being effec- 
tive in vivo, in contrast to guanidine and 2- (a-hydroxybenzy1)-benzimidazole, 
where resistance does vitiate their effectiveness in monkeys.18-20 
Our present studies on the locus and mechanism of the antiviral activity of 
amantadine involve its use in comparison and conjunction with other agents of 
known activity. The application of X-ray to impair early immune responses in- 
dicated that specific antibody was not a necessary complement to amantadine 
activity in vivo. When amantadine was compared in vitro to aminophenylmethane 
sulfonic acid, an inhibitor of influenza virus with a known locus of activity, the 
two compounds were found to be essentially equivalent and interchangeable in 
their abilities to inhibit influenza virus and to induce mutual resistance. Neither 
inhibitor was reversed with selected amino acids.'5 
Rubella virus, in contrast to influenza virus, retained its susceptibility to inhibi- 
tion by amantadine, even when grown in chronically infected cells where its 
production was not decreased by amantadine treatment. Amantadine's similarity 
to aminophenylmethane sulfonic acid, which acts early in the cycle of virus repli- 
cation during adsorption or penetration,I6 supports the earlier suggestion by 
Davies et a/.' that amantadine interferes with virus penetration, and is compatible 
with its decreased effectiveness in delayed treatment against rubella virus in vitro.5 
Since the chronic in vitro rubella infection was not susceptible, the mode of 
action of amantadine enables one to conclude that the RA cell line8 represents a 
true chronic infection, maintained intracellularly as the cells divide, and not going 
through an amantadine-susceptible penetration phase. It is tempting to speculate 
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that the development of resistance to amantadine by influenza virus and the per- 
sistence of susceptibility by rubella virus may be related to their immunologic 
mutabilities-influenza virus having the more variable surface, as reflected by its 
many and changing serotypes, compared with rubella virus's more stable surface 
and apparently single serotype. 
Amantadine attracted attention through its interesting structure, and seems to 
be maintaining its attraction in the current laboratory and early clinical testing 
phases. Its clinical testing requires time and experience, but in any event amanta- 
dine is making a significant contribution to the present, accelerating growth of 
interest and accomplishment, exemplified in part by this symposium, in the 
chemotherapy and chemoprophylaxis of viral diseases. 
Summary 
Amantadine hydrochloride at concentrations not toxic to host cells or free 
virus inhibited the growth of parainfluenza types 2 and 3 and respiratory 
syncytial viruses in vitro. 
In mice infected by virus aerosols, protection by amantadine was confirmed 
against A and A2 strains and was demonstrated against type B influenza. Vac- 
cinial lung lesions in mice were not inhibited, while in ferrets amantadine treat- 
ment aggravated influenza. 
Amantadine protected both nonirradiated and irradiated mice and was additive 
with X-ray in exerting a sparing effect. 
The growth of rubella virus in chronically-infected LLC-MK2 cells was not 
inhibited by amantadine. This lack of inhibition was not due to the development 
of resistance by rubella virus, since acute infection of cells with virus produced in 
treated, chronically infected cells was susceptible. Rubella virus passed repeatedly 
in acutely infected, treated cells also retained susceptibility to amantadine. In 
contrast, influenza virus readily developed resistance in treated, acutely infected 
primary calf kidney cell cultures. When the inhibitory activity of amantadine 
hydrochloride was compared with aminophenylmethane sulfonic acid, a type of 
inhibitor acting early in the infectious cycle, both were found similarly effective 
in suppressing influenza virus production in vitro applied preinfection but not 
post-infection, and that inhibition due to either was maintained equally well by the 
other. Influenza virus made resistant to amantadine hydrochloride or amino- 
phenylmethane sulfonic acid in vitro was also cross resistant to the other. This 
interchangeability for both inhibition and resistance was interpreted as indicating 
common sites of activity. 
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